Drug interactions
Candesartan + Insulin neutral human-insulin isophane protamine human
Severity: Minor
Candesartan and Insulin neutral human-insulin isophane protamine human: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Angiotensin receptor blockers may improve insulin sensitivity and occasionally enhance the glucose-lowering effect of insulin. This can occasionally lead to hypoglycemia in insulin-treated patients.
What this interaction means in plain words
Candesartan and Insulin neutral human-insulin isophane protamine human have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Candesartan belongs to Cardiovascular; Insulin neutral human-insulin isophane protamine human belongs to Endocrine.
Why it happens
Possible improvement of insulin sensitivity by angiotensin receptor blockade; the mechanism is not firmly established.
What to do
Monitor glucose when starting or changing candesartan and adjust insulin if hypoglycemia occurs.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Candesartan and Insulin neutral human-insulin isophane protamine human, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Insulin neutral human-insulin isophane protamine human
- Ethanol + Insulin neutral human-insulin isophane protamine human Major
- Insulin neutral human-insulin isophane protamine human + Pentamidine Major
- Insulin neutral human-insulin isophane protamine human + Rosiglitazone Major
- Acarbose + Insulin neutral human-insulin isophane protamine human Moderate
- Albiglutide + Insulin neutral human-insulin isophane protamine human Moderate
- Alogliptin + Insulin neutral human-insulin isophane protamine human Moderate
Other interactions of Candesartan
- Aliskiren + Candesartan Contraindicated
- Candesartan + Sparsentan Contraindicated
- Amifostine + Candesartan Major
- Amiloride + Candesartan Major
- Amlodipine-benazepril + Candesartan Major
- Amlodipine-hydrochlorothiazide-valsartan + Candesartan Major
Frequently asked questions
Can I take Candesartan with Insulin neutral human-insulin isophane protamine human?
MediHelp rates the interaction as minor. Candesartan and Insulin neutral human-insulin isophane protamine human have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Angiotensin receptor blockers may improve insulin sensitivity and occasionally enhance the glucose-lowering effect of insulin. This can occasionally lead to hypoglycemia in insulin-treated patients.
How serious is the interaction between Candesartan and Insulin neutral human-insulin isophane protamine human?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor glucose when starting or changing candesartan and adjust insulin if hypoglycemia occurs.
What other medicines interact with Insulin neutral human-insulin isophane protamine human?
MediHelp also lists interactions of Insulin neutral human-insulin isophane protamine human with, for example, Ethanol, Pentamidine, Rosiglitazone. The full list is on the Insulin neutral human-insulin isophane protamine human page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
